Maravai LifeSciences Holdings Inc. Class A Common Stock vs Target Corporation — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Target Corporation trades at $156.73 (market cap $69.05B). The key difference: Target Corporation is far larger — about 71× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Target Corporation pays a 3.05% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Target Corporation for 137 Days on average.
| MRVI | TGT | |
|---|---|---|
Market Cap | $972.90M | $69.05B |
Volume | 4,325,710 | 3,728,482 |
Sector | Health | Consumer Staples |
52-Week High | $9.00 | $169.90 |
52-Week Low | $2.83 | $83.68 |
Typical Hold Time | 0 Days | 137 Days |
Enterprise Value | $1.08B | $82.33B |
Dividend Yield | — | 3.05% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Target (TGT) trades at $155.30, up 1.13% today, with a neutral technical signal and key resistance at $155. The stock shows strong profitability with a 26.41% ROE and 4.08% net margin, supported by three consecutive quarterly earnings beats. Recent news highlights holiday price cuts to capture market share, while analyst consensus is evenly split between Buy and Hold ratings.
The outlook is balanced: valuation appears reasonable with a P/E of 15.77, and dividend stability offers income appeal, but competitive pressures and margin compression from aggressive pricing pose risks. Upside to the $166.95 consensus target depends on successful execution of growth initiatives amid a challenging retail environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →